Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 3/20 | 0.37 |
| ▸ | PLK1 | P53350 | 2/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14331681 | 0.92 | STK17A (0.42) | STAT6TNK2PTK2BRD4WEE1 | |
| SCHEMBL10205211 | 0.91 | CDK1 (0.40) | TNK2CDK1PTK2BRD4WEE1 | |
| SCHEMBL10206634 | 0.90 | STAT6 (0.44) | STAT6TNK2CDK1PTK2PTK2B | |
| SCHEMBL10205863 | 0.89 | STAT6 (0.43) | STAT6TNK2CDK1PTK2BRD4 | |
| SCHEMBL10206186 | 0.89 | TNK2 (0.45) | TNK2PTK2FLT4IGF1R | |
| SCHEMBL10206198 | 0.88 | STAT6 (0.42) | STAT6TNK2CDK1PTK2BRD4 | |
| SCHEMBL10205220 | 0.87 | STAT6 (0.42) | STAT6TNK2CDK1PTK2BRD4 | |
| SCHEMBL10207050 | 0.86 | TNK2 (0.54) | TNK2CDK1PTK2WEE1PTK2B | |
| SCHEMBL14331602 | 0.85 | STAT6 (0.43) | STAT6TNK2CDK1PTK2PTK2B | |
| SCHEMBL10205861 | 0.85 | STAT6 (0.43) | STAT6TNK2CDK1PTK2PTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012085126-A1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | MKI67, CCNI, CCNB1 | STAT6 1155/4885TNK2 646/4885CDK1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.